Omnicell Raises 2026 EPS Outlook as Memory Costs Pressure Margins

Omnicell, Inc. OMCL raised its 2026 earnings outlook after a better-than-expected second quarter, but part of the profit improvement came from a one-time tariff refund.

The next test is whether operating discipline can absorb higher memory-chip costs while bookings and recurring-revenue conversion remain sensitive to hospital purchasing timelines.

Omnicell Lifted Its 2026 Earnings Outlook

Omnicell now expects adjusted earnings of $2.15-$2.30 per share for 2026, up from $1.80-$2.00 previously. Non-GAAP EBITDA guidance increased to $175-$185 million.

Second-quarter adjusted earnings reached 94 cents per share, up 108.9% year over year and 95.8% above the Zacks Consensus Estimate. Revenues rose 7.4% to $312.2 million and exceeded the consensus mark by 0.8%.

Based on short-term price targets offered by seven analysts, the average price target for Omnicell comes to $57.86. The average price target represents an increase of 55.83% from the last closing price. 

Image Source: Zacks Investment Research

OMCL’s Tariff Refund Flattered Second-Quarter Profit

Second-quarter non-GAAP EBITDA totaled $67 million, including a one-time $15 million refund of previously paid IEEPA tariffs. That benefit lifted product gross margin and earnings but will not recur.

Excluding the refund, non-GAAP EBITDA would have been $52 million. That still came in above the midpoint of prior guidance, indicating that the quarter’s underlying profitability was not solely dependent on the tariff benefit.

Omnicell Faces a $6 Million Memory Cost Headwind

Memory-chip supply-demand imbalance is expected to add about $6 million of incremental cost in the second half of 2026, roughly five times the level expected at the beginning of the year.

Management expects the pressure to reduce full-year consolidated gross margin by about 50 basis points and product gross margin by about 80 basis points. Continued component inflation or supply constraints could further limit margin expansion.

OMCL’s Cost Discipline Could Offset Some Pressure

Management attributed underlying second-quarter performance to revenue mix, cost control and operating efficiency. Those levers could help preserve earnings leverage as the tariff refund disappears and memory costs rise.

Hospital medication technology remains an active investment area. Becton, Dickinson and Company BDX offers connected medication-management systems, including automated dispensing and inventory tools, while Baxter International Inc. BAX markets connected infusion platforms used in medication delivery.

Omnicell’s Guidance Test Extends Beyond Margins

Full-year revenue guidance stands at $1.225-$1.245 billion. Omnicell also widened product-bookings guidance to $425-$560 million as management reassessed the timing of medium-sized and large health-system transactions.

Year-end annual recurring revenue guidance was reduced to $660-$680 million because certain consumables opportunities are taking longer to develop. A younger XT installed base and lengthy hospital approval cycles could also slow the timing of the Titan XT refresh.

In the past year, OMCL shares have risen 18.5% against the industry’s 15% decline. 

Image Source: Zacks Investment Research

OMCL’s Ratings Frame the Event Risk

The raised earnings outlook improves the 2026 profit picture, but its durability depends on cost control, stable revenue conversion and the timing of larger customer decisions as input costs rise.

OMCL currently carries a Zacks Rank #5 (Strong Sell), alongside a Growth Score of A, Value Score of B, Momentum Score of B and VGM Score of A. The favorable Style Scores point to attractive growth, value and momentum characteristics, but the Zacks Rank remains the primary near-term signal and indicates unfavorable earnings-estimate revision trends.

You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research